Sep 28 2026 11:39 PM EST

Zoetis Shares Slide as Revenue Outlook Softens and Regulatory Scrutiny Mounts

Zoetis Inc. (NYSE: ZTS) has fallen 36.6% over the last six months, leaving the stock at roughly $71.20. The slide reflects a combination of flat U.S. sales, a downgrade to organic‑growth guidance for FY 2026, and growing regulatory focus on its monoclonal‑antibody pain products. Investors are now weighing whether the company’s modest earnings growth and margin expansion can offset these headwinds.

Guidance Cut Signals Slower Growth

In September 2026 Zoetis trimmed its FY 2026 revenue outlook to a range of $9.825 billion–$10.025 billion, implying organic growth of only ‑1% to ‑3%. The prior guidance had called for 3%–5% organic growth. Adjusted diluted EPS is now projected at $7.00–$7.10, down from earlier expectations. The revision follows a flat U.S. revenue profile (0% YoY) and a 5% decline in companion‑animal revenue in Q2 2026.

Regulatory Pressure on Pain Biologics

The U.S. Center for Veterinary Medicine (CVM) tightened post‑market safety oversight of the company’s monoclonal‑antibody pain franchise – Librela (canine) and Solensia (feline). Both products account for a growing share of the companion‑animal portfolio, and any adverse safety signal could curb sales or trigger additional compliance costs. The regulatory environment adds uncertainty to the pipeline, even as new European products Lenivia and Portela have secured approvals.

Revenue Mix and Margin Trends

Zoetis reported FY 2025 revenue of $9.467 billion, up 2% YoY, with companion‑animal sales at $6.587 billion (+5% YoY) and livestock sales declining 5% to $2.764 billion. International revenue grew 4% YoY to $4.254 billion, driven by a 5% organic increase, while U.S. revenue remained flat. Gross margin improved to 83.5% in the U.S. segment and 69.2% internationally, reflecting favorable product mix and cost‑of‑sales efficiencies. Adjusted net income rose 6% YoY to $2.847 billion, supporting a diluted EPS of $6.02.

Valuation and Market Reaction

Despite a trailing P/E of 11.7× and a dividend yield of 2.93%, the stock trades well below its historical average, reflecting a market‑wide discount to earnings growth (PEG ≈ 2.62). Short interest sits at 4.22% of float, indicating continued bearish positioning. Technical indicators in September 2026 show a bearish bias, with the 10‑day moving average crossing below the 50‑day average and momentum momentum indicators turning negative.

Risks and Uncertainties

Key risks include continued softness in companion‑animal spending, potential safety findings for Librela and Solensia, and foreign‑exchange volatility that could erode international gains, especially in China where sales fell 23% in Q4 2025. Additionally, the company’s reliance on a limited number of high‑margin products makes it vulnerable to competitive pressure from generics and emerging biologics. Any further regulatory setbacks or slower‑than‑expected uptake of new European products could deepen the share‑price decline.